KING OF PRUSSIA, Pa., July 19, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental Biologics License Application (BLA) for Hizentra (R) [Immune globulin subcutaneous...Read More
BERLIN, July 12, 2017 /PRNewswire/ -- CSL Behring today presented data finding that prophylaxis treatment with IDELVION (R) provides consistently high factor IX levels, resulting in low bleeding rates in both adult and paediatric patients with haemophilia B. Results were presented at the Internat...Read More
SITGES, Spain, July 11, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced at the Peripheral Nerve Society's annual meeting the winners of its annual Interlaken Leadership Awards. There are two 2017 recipients of this global awards program which provides monetary...Read More
BERLIN, July 10, 2017 /PRNewswire/ -- CSL Behring today presented data finding treatment with AFSTYLA (R) may result in low average product consumption without compromising efficacy in both the prophylaxis and on-demand settings. Results were presented at the International Society on Thrombosis...Read More
MARBURG, Germany, July 6, 2017 /PRNewswire/ -- CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2017 in Berlin, Germany, July 8 - 13, 2017. Six poster...Read More
VANCOUVER, BC--(Marketwired - July 05, 2017) - Comstock Metals Ltd. (TSX VENTURE: CSL) ("Comstock" or the "Company") is pleased to announce that it has commenced a summer exploration program at its 100% owned Preview SW gold project, located 40 km northeast of La Ronge, Saskatchewan. This phas...Read More
KING OF PRUSSIA, Pa., June 23, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved HAEGARDA (R) (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous therap...Read More
MELBOURNE, Australia, April 19, 2017 /PRNewswire/ -- Global biotherapeutics leader, CSL Behring today announced that the Australian Therapeutic Goods Administration (TGA) has approved AFSTYLA (R) [lonoctocog alfa] a recombinant single chain coagulation factor VIII (rFVIIISingleChain) in patients...Read More
VANCOUVER, BC --(Marketwired - May 18, 2017) - Gracetree Investments, LLC ("Gracetree") announces that it has filed an early warning report in respect of its acquisition on February 27, 2017 (the "Closing Date") of 3,333,333 units (the "Units") of Comstock Metals Ltd. (the "Company"), by way of...Read More
KING OF PRUSSIA, Pa., May 19, 2017 /PRNewswire/ -- CSL Behring received the National Organization for Rare Disorders' (NORD) 2017 Industry Innovation Award last night in Washington, D.C. for pioneering new medicines. The biotech leader was recognized for developing its long-acting fusion pro...Read More
MELBOURNE, Australia, June 12, 2017 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) announced today that it has agreed to acquire 80 per cent equity of plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. ("Ruide") from Humanwell Healthcare Group Co. Ltd.(...Read More
VANCOUVER, BC--(Marketwired - June 19, 2017) - Comstock Metals Ltd. (TSX VENTURE: CSL) ("Comstock" or the "Company") is pleased to provide an update on 2017 exploration plans for its +16,000 hectare wholly-owned QV gold project located in the heart of the prolific White Gold district of the Yu...Read More